
    
      This is a single-site, single-arm, open-label, drug-interaction study that examines the
      effect of rifaximin (RFX), 550 mg 3 times daily (TID; 1650 mg/day), on orally administered
      (PO) midazolam (MDZ) 2 mg (administered as a 2 mg dose in 1 mL of midazolam HCL Syrup; 2
      mg/mL) when dosed for 7 and 14 consecutive days, respectively.
    
  